Lenalidomida Fresenius Kabi

Lenalidomide, the active ingredient in Lenalidomida Fresenius Kabi, is an immunomodulatory drug presented as an oral tablet for systemic use. It is employed in the treatment of certain blood cancers, notably multiple myeloma and myelodysplastic syndromes, specifically in adult patients who have received prior therapy.

GNH USA supplies Lenalidomida Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company follows stringent quality standards and offers reliable logistics to ensure timely supply.

Lenalidomide is used in hematologic malignancies that respond to immunomodulatory therapy.

- Multiple Myeloma: improves disease control and extends survival in patients with relapsed or refractory disease. - Myelodysplastic Syndromes: reduces transfusion dependence and delays progression to acute leukemia in lower‑risk patients. - Multiple Myeloma (maintenance): administered continuously after initial response to prolong remission.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause easy bruising. - Diarrhea: loose stools that may be mild to moderate. - Rash: skin irritation or erythema. - Constipation: difficulty passing stool.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers. - Severe neutropenia: profound drop in neutrophils requiring hospitalization. - Severe infections: opportunistic or bacterial infections. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should assess baseline parameters and monitor patients closely.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess renal function: adjust therapy if creatinine clearance is reduced. - Avoid pregnancy: use effective contraception for both patient and partner. - Vaccination: administer required vaccines before starting treatment. - Review concomitant drugs: evaluate for potential interactions. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - CYP450 inducers (e.g., rifampin): may lower lenalidomide exposure. - Strong anticoagulants (e.g., warfarin): increase bleeding risk. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., clarithromycin): may raise plasma levels. - Azole antifungals (e.g., ketoconazole): can increase exposure. - Immunosuppressants (e.g., cyclosporine): additive myelosuppression potential.